Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

China · Delayed Price · Currency is CNY

20.44

+0.70 (3.55%)

Sep 30, 2026, 3:04 PM CST

Market Cap	9.77B -39.3%
Revenue (ttm)	187.53M -30.0%
Net Income	-89.90M
EPS	-0.19
Shares Out	477.77M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,130,407
Open	20.65
Previous Close	19.74
Day's Range	19.71 - 20.98
52-Week Range	18.98 - 42.65
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHE:300204

Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respiratory and critical care illnesses, and neurological disorders. Its product portfolio includes Mouse Nerve Growth factor for injection, Compound Polyet... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 491

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300204

Full Company Profile

Financial Performance

In 2025, SHE:300204's revenue was 220.23 million, a decrease of -32.20% compared to the previous year's 324.82 million. Losses were -77.76 million, -46.31% less than in 2024.

Financial Statements